Clearside Biomedical News

Clearside Biomedical Q2 2024 Earnings Preview

Seeking Alpha17:35 ET

Clearside Biomedical to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

GlobeNewswireAug 8 07:05 ET

Clearside Biomedical, Inc. (CLSD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Yahoo FinanceAug 5 10:00 ET

Clearside Biomedical to Report Second Quarter 2024 Financial Results on Monday, August 12, 2024

GlobeNewswireAug 1 07:05 ET

Clearside Biomedical Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow JonesJul 30 13:55 ET · Ratings

H.C. Wainwright Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsJul 30 12:32 ET · Ratings

Buy Rating Affirmed for Clearside Biomedical on Promising Phase 3 Results and Innovative Drug Delivery System

TipRanksJul 30 12:25 ET · Ratings

Buy Rating Affirmed for Clearside Biomedical on Successful Drug Delivery Innovations and Positive Clinical Results

TipRanksJul 29 19:35 ET · Ratings

Express News | Clearside Biomedical Partner Arctic Vision Reports Phase 3 Results For ARCATUS In Uveitic Macular Edema; NDAs For ARCATUS Accepted In Australia And Singapore

BenzingaJul 29 16:24 ET

Express News | Clearside Biomedical: Arctic Vision Announced That New Drug Applications for Arcatus Have Been Officially Accepted in Australia and Singapore

ReutersJul 29 16:05 ET

Express News | Clearside Biomedical’s Partner Arctic Vision Reports Positive Topline Results From Phase 3 Clinical Trial of Arcatus® for Suprachoroidal Use in Uveitic Macular Edema Patients in China

ReutersJul 29 16:05 ET

Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results From Phase 3 Clinical Trial of ARCATUS for Suprachoroidal Use in Uveitic Macular Edema Patients in China

GlobeNewswireJul 29 16:05 ET

Oppenheimer Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsJul 26 08:31 ET · Ratings

Oppenheimer Sticks to Its Buy Rating for Clearside Biomedical (CLSD)

TipRanksJul 26 08:18 ET · Ratings

Express News | Needham Reiterates Buy on Clearside Biomedical, Maintains $4 Price Target

BenzingaJul 25 06:01 ET

JMP Securities Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsJul 24 16:31 ET · Ratings

Clearside Biomedical's Promising CLS-AX Treatment in the ODYSSEY Trial: A Buy Rating Based on Safety and Potential Market Impact

TipRanksJul 24 15:45 ET · Ratings

Needham Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsJul 24 15:32 ET · Ratings

Buy Rating Affirmed: Clearside Biomedical's Innovative Drug Delivery and Promising Clinical Trials

TipRanksJul 24 15:05 ET · Ratings

Clearside Biomedical Hosts Suprachoroidal Delivery Webinar

TipRanksJul 24 08:17 ET